CVRx, Inc.

NASDAQ:CVRX

Medical - Devices

Healthcare
$2.63 +2.28%

+$0.11 today

Market cap
$69.79M
Beta
0.77
P/E (TTM)
-2.5
EPS (TTM)
-$2.00
52W Low $4.37High $11.30

Volume 0.37M

Average 0.30M

CVRX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

CVRx, Inc.NASDAQ: CVRX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $205K rose 11.4% year over year, behind the +15.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.8% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Depreciation & amortization amounted to 1.3% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.4% toward the trailing-twelve-month pace of +15.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$205K+10.8% QoQ
Last fiscal yearDec 2025
$756K+22.1% YoY
LTMMar 2026
$777K+15.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.4%——
1 year+22.1%——
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
756K USD
Year-over-year change
+22.1%
4-year CAGR
+45.6%

Depreciation & Amortization vs competitors

How CVRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.6% is the 4th highest of 10, against a peer median of -0.3%.
  • Depreciation & amortization amounts to 1.3% of revenue for CVRX, versus a peer median of 7.5%.
CVRX Competitors
Depreciation & Amortization for CVRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VMDViemed Healthcare, Inc.LTM Mar 2026$29.62M USD+15.3%+22.3%10.3%
QTRXQuanterix CorporationLTM Mar 2026$21.08M USD+133.7%+51.8%14.5%
NNOXNano-X Imaging Ltd.LTM Dec 2025$11.7M USD-0.3%+0.5%89.8%
MASS908 Devices Inc.LTM Mar 2026$4.32M USD-7.0%+40.4%7.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
CERSCerus CorporationLTM Mar 2026$2.28M USD+49.0%-12.5%1.0%
SENSSenseonics Holdings, Inc.LTM Mar 2026$1.67M USD-1.0%+15.4%4.1%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$1.59M USD+32.3%+10.5%3.6%
CVRXCVRx, Inc.LTM Mar 2026$777K USD+15.6%+22.4%1.3%
SGHTSight Sciences, Inc.LTM Mar 2026$441K USD-24.4%-27.0%0.6%
Peer median (excluding CVRX) —-0.3%+10.5%7.5%

Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.04M22.47M39.3M51.29M56.65M
Cost of Revenue3.64M5M6.26M8.33M8.31M
Gross Profit9.4M17.47M33.04M42.96M48.34M
Gross Margin72.1%77.8%84.1%83.8%85.3%
Research & Development7.5M9.95M11.63M11.13M11.13M
Selling, General & Admin27.86M50.05M64.51M91.32M88.47M
Operating Expenses35.36M60M76.14M102.45M99.61M
Depreciation & Amortization168K412K522K619K756K
EBITDA(40.6M)(40.74M)(38.73M)(54.89M)(46.74M)
EBITDA Margin-311.4%-181.3%-98.6%-107.0%-82.5%
Operating Income(25.97M)(42.53M)(43.1M)(59.49M)(51.27M)
Operating Margin-199.2%-189.3%-109.7%-116.0%-90.5%
Interest Income00000
Interest Expense2.22M165K1.8M4.4M5.83M
Other Income / Expenses(17.02M)1.21M2.05M(420K)(2.06M)
Income Before Tax(42.99M)(41.32M)(41.05M)(59.91M)(53.32M)
Pre-Tax Margin-329.8%-183.9%-104.5%-116.8%-94.1%
Income Tax Expense91K109K147K55K(18K)
Net Income(43.08M)(41.43M)(41.2M)(59.97M)(53.31M)
Net Margin-330.5%-184.4%-104.8%-116.9%-94.1%
EPS (Basic)(2.11)(2.02)(1.99)(2.65)(2.04)
EPS (Diluted)(2.11)(2.02)(1.99)(2.65)(2.04)
Weighted Avg Shares20.72M20.51M20.7M22.6M26.08M
Weighted Avg Shares (Diluted)20.72M20.53M20.75M22.6M26.08M

CVRx, Inc.

NASDAQ:CVRX

Intrinsic Alpha fair value

Locked

Current Price

$2.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.